Target Information

Target General Infomation
Target ID
T92609
Former ID
TTDC00292
Target Name
Alpha-1A adrenergic receptor
Gene Name
ADRA1A
Synonyms
Alpha 1A-adrenoceptor; Alpha 1A-adrenoreceptor; Alpha adrenergic receptor 1c; Alpha-1C adrenergic receptor; ADRA1A
Target Type
Successful
Disease Benign prostatic hyperplasia [ICD9: 600; ICD10: N40]
Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10: F01-F07, F04, F05, R41.3]
Female sexual dysfunction [ICD9: 302.7; ICD10: F52]
Glaucoma [ICD9: 365; ICD10: H40-H42]
Hypertension [ICD9: 401; ICD10: I10-I16]
Heart arrhythmia [ICD10: I47-I49]
Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10: F32, F33, M32]
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89]
Prostate hyperplasia [ICD10: N40]
Prostate cancer; Benign prostatic hyperplasia [ICD9: 140-229, 185, 600; ICD10: C61, N40]
Prostate disease [ICD10: N42.9]
Post-traumatic stress disorder [ICD9: 309.81; ICD10: F43.1]
Stress urinary incontinence [ICD10: N39.3]
Urinary incontinence [ICD9: 788.3; ICD10: N39.3, N39.4, R32]
Unspecified [ICD code not available]
Function
This alpha-adrenergic receptor mediates its action by association with g proteins that activate a phosphatidylinositol- calcium second messenger system, and its effect is mediated by G(q) and G(11) proteins.
BioChemical Class
GPCR rhodopsin
Target Validation
T92609
UniProt ID
P35348
Sequence
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSV
THYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCII
SIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINE
EPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKN
APAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPD
FKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTL
HPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCT
TARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSENGEEV
Drugs and Mode of Action
Drug(s) NAFTOPIDIL Drug Info Approved Hypertension [1]
SILODOSIN Drug Info Approved Benign prostatic hyperplasia [2], [3], [4]
Tamsulosin Drug Info Approved Benign prostatic hyperplasia [5], [6]
Xatral Drug Info Approved Benign prostatic hyperplasia [1]
Besipirdine Drug Info Phase 3 Cognitive disorders [7]
Dutasteride + tamsulosin Drug Info Phase 3 Prostate cancer; Benign prostatic hyperplasia [8]
MEDETOMIDINE Drug Info Phase 2 Pain [9]
CM-2236 Drug Info Preclinical Post-traumatic stress disorder [10]
Sunepitron Drug Info Discontinued in Phase 3 Discovery agent [11]
TIOSPIRONE Drug Info Discontinued in Phase 3 Discovery agent [12], [13]
L-771688 Drug Info Discontinued in Phase 2 Prostate disease [14]
MAZAPERTINE Drug Info Discontinued in Phase 2 Discovery agent [15]
RBx-2258 Drug Info Discontinued in Phase 2 Prostate hyperplasia [16]
SOU-001 Drug Info Discontinued in Phase 2 Urinary incontinence [17]
Taprizosin Drug Info Discontinued in Phase 2 Prostate hyperplasia [18]
UPIDOSIN Drug Info Discontinued in Phase 2 Discovery agent [19], [20]
RS-100975 Drug Info Discontinued in Phase 1 Prostate disease [21], [22]
SDZ-NVI-085 Drug Info Discontinued in Phase 1 Major depressive disorder [23]
A-131701 Drug Info Terminated Discovery agent [24]
A-204176 Drug Info Terminated Stress urinary incontinence [25]
ABANOQUIL Drug Info Terminated Discovery agent [26]
AGN-193080 Drug Info Terminated Discovery agent [27]
BMY-7378 Drug Info Terminated Discovery agent [28], [29]
KRG-3332 Drug Info Terminated Glaucoma [30]
L-757464 Drug Info Terminated Prostate hyperplasia [31]
NIGULDIPINE Drug Info Terminated Discovery agent [32], [33]
Siramesine Drug Info Terminated Discovery agent [34]
SK&F-104078 Drug Info Terminated Discovery agent [35]
SK&F-104856 Drug Info Terminated Discovery agent [36]
SNAP-5089 Drug Info Terminated Heart arrhythmia [37], [38]
SNAP-6201 Drug Info Terminated Discovery agent [39]
WB-4101 Drug Info Terminated Discovery agent [40], [41]
Sunepitron Drug Info Investigative Unspecified [42]
Inhibitor (+/-)-nantenine Drug Info [43]
(-)-SNAP-5399 Drug Info [44]
(2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine Drug Info [45]
(2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine Drug Info [45]
1',2',3',6'-Tetrahydro-[2,4']bipyridinyl Drug Info [46]
1-(2-Chloro-phenyl)-piperazine Drug Info [47]
1-(2-Methoxy-phenyl)-piperazine Drug Info [47]
1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine Drug Info [46]
1-(pyridin-2-yl)piperazine Drug Info [46]
2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole Drug Info [48]
2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline Drug Info [49]
4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole Drug Info [50]
4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole Drug Info [50]
4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole Drug Info [51]
4-(1-Naphthalen-1-yl-propyl)-1H-imidazole Drug Info [50]
4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole Drug Info [50]
4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole Drug Info [50]
4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline Drug Info [49]
4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol Drug Info [52]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Drug Info [53]
4-(4-chlorobenzyl)-2-allylphthalazin-1(2H)-one Drug Info [54]
4-(4-chlorobenzyl)-2-methylphthalazin-1(2H)-one Drug Info [54]
4-(4-chlorobenzyl)phthalazin-1(2H)-one Drug Info [54]
4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol Drug Info [52]
4-(4-Methyl-indan-1-yl)-1H-imidazole Drug Info [55]
4-Benzo[b]thiophen-4-yl-1H-imidazole Drug Info [56]
4-benzyl-2-methylphthalazin-1(2H)-one Drug Info [54]
4-Morpholin-2-yl-benzene-1,2-diol Drug Info [52]
5-Bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine Drug Info [57]
8-Piperazin-1-yl-imidazo[1,2-a]pyrazine Drug Info [57]
A-119637 Drug Info [44]
A-123189 Drug Info [44]
A-131701 Drug Info [44]
A-315456 Drug Info [44]
ABANOQUIL Drug Info [58]
AGN-192172 Drug Info [59]
AGN-193080 Drug Info [59]
BMY-7378 Drug Info [60]
CORYNANTHEINE Drug Info [44]
FLUANISONE Drug Info [61]
Imidazolidin-2-ylidene-o-tolyl-amine Drug Info [59]
Imidazolidin-2-ylidene-quinoxalin-6-yl-amine Drug Info [59]
ISOCLOZAPINE Drug Info [62]
L-765314 Drug Info [44]
L-771688 Drug Info [44]
LEVONORDEFRIN Drug Info [50]
MAZAPERTINE Drug Info [63]
MEDETOMIDINE Drug Info [51]
N-(5-Bromo-quinoxalin-6-yl)-guanidine Drug Info [59]
NAFTOPIDIL Drug Info [44]
NIGULDIPINE Drug Info [64]
OCTOCLOTHEPIN Drug Info [65]
R-226161 Drug Info [66]
Ro-11-04253 Drug Info [44]
RS-100329 Drug Info [44]
RS-513815 Drug Info [44]
RWJ-38063 Drug Info [44]
RWJ-68141 Drug Info [44]
RWJ-68157 Drug Info [44]
RWJ-69736 Drug Info [44]
RX-821002 Drug Info [67]
SILODOSIN Drug Info [44]
Siramesine Drug Info [68]
SK&F-104078 Drug Info [64]
SK&F-104856 Drug Info [64]
SK&F-105854 Drug Info [44]
SK&F-106686 Drug Info [64]
SK&F-86466 Drug Info [64]
SNAP-5036 Drug Info [44]
SNAP-5089 Drug Info [64]
SNAP-6201 Drug Info [44]
SNAP-7915 Drug Info [44]
SNAP-8719 Drug Info [60]
SNAP-94847 Drug Info [69]
SPIPERONE Drug Info [44]
Sunepitron Drug Info [42]
TIOSPIRONE Drug Info [70]
UH-301 Drug Info [71]
UPIDOSIN Drug Info [44]
WB-4101 Drug Info [58]
Agonist 4-Methoxyamphetamine Drug Info [72]
A-204176 Drug Info [73]
CM-2236 Drug Info [74]
Antagonist Besipirdine Drug Info [75]
Dutasteride + tamsulosin Drug Info [76]
GG-818 Drug Info [77]
KRG-3332 Drug Info [78]
L-757464 Drug Info [79]
RBx-2258 Drug Info [80]
REC2615 Drug Info [81]
RS-100975 Drug Info [82]
SDZ-NVI-085 Drug Info [83]
Taprizosin Drug Info [84]
Xatral Drug Info [85]
Modulator SOU-001 Drug Info [86]
Tamsulosin Drug Info [87]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Calcium signaling pathway
cGMP-PKG signaling pathway
Neuroactive ligand-receptor interaction
AMPK signaling pathway
Adrenergic signaling in cardiomyocytes
Vascular smooth muscle contraction
Salivary secretion
PANTHER Pathway Alpha adrenergic receptor signaling pathway
Reactome Adrenoceptors
G alpha (q) signalling events
G alpha (12/13) signalling events
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Endothelin Pathways
GPCR ligand binding
GPCR downstream signaling
AMPK Signaling
References
REF 1Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF 2(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 493).
REF 32008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
REF 4Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Clin Ther. 2009 Nov;31(11):2489-502.
REF 5(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 488).
REF 6Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90.
REF 7Clinical pipeline report, company report or official report of UroGene.
REF 8ClinicalTrials.gov (NCT00090103) Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment. U.S. National Institutes of Health.
REF 9Sedative and cardiopulmonary effects of medetomidine hydrochloride and xylazine hydrochloride and their reversal with atipamezole hydrochloride in calves. Am J Vet Res. 2008 Mar;69(3):319-29.
REF 10Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029346)
REF 11Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004255)
REF 12(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 101).
REF 13Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000562)
REF 14Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014018)
REF 15Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002662)
REF 16Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011920)
REF 17Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014478)
REF 18Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017098)
REF 19(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 496).
REF 20Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003537)
REF 21(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 497).
REF 22Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013213)
REF 23Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001726)
REF 24Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008617)
REF 25Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013646)
REF 26Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000128)
REF 27Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008130)
REF 28(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 9).
REF 29Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001317)
REF 30Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018805)
REF 31Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010051)
REF 32(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 487).
REF 33Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002398)
REF 34Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001859)
REF 35Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000354)
REF 36Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001560)
REF 37(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 498).
REF 38Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006771)
REF 39Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009143)
REF 40(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 499).
REF 41Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004048)
REF 42J Med Chem. 2006 Jun 1;49(11):3116-35.An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
REF 43Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. Epub 2009 Nov 20.Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.
REF 44Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.Pharmacophore identification of alpha(1A)-adrenoceptor antagonists.
REF 45J Med Chem. 1997 Jan 3;40(1):18-23.Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists.
REF 46J Med Chem. 1984 Sep;27(9):1182-5.Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
REF 47J Med Chem. 1991 Jun;34(6):1850-4.Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands.
REF 48Bioorg Med Chem Lett. 2004 Sep 20;14(18):4697-9.2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands.
REF 49Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists.
REF 50J Med Chem. 1996 Jul 19;39(15):3001-13.Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene derivatives of medetomidine.
REF 51J Med Chem. 1994 Jul 22;37(15):2328-33.A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic receptors.
REF 52J Med Chem. 1992 Mar 20;35(6):1009-18.Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.
REF 53J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
REF 54Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90. Epub 2006 Mar 2.Vasorelaxant activity of phthalazinones and related compounds.
REF 55J Med Chem. 1997 Sep 12;40(19):3014-24.Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potential binding interactions with alpha 2-adrenoceptors involving a "methyl pocket".
REF 56J Med Chem. 2000 Mar 9;43(5):765-8.alpha(2) Adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene [corrected] as a high-affinity ligand for the alpha(2D) adrenergic receptor.
REF 57J Med Chem. 1992 Oct 16;35(21):3845-57.Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines.
REF 58J Med Chem. 1995 Sep 1;38(18):3415-44.Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
REF 59Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995).
REF 60J Med Chem. 2005 Apr 21;48(8):3076-9.Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione as selective alpha(1d)-adrenergic receptor antagonists.
REF 61J Med Chem. 1987 Nov;30(11):2099-104.2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1.
REF 62J Med Chem. 1997 Dec 5;40(25):4146-53.Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic.
REF 63J Med Chem. 1994 Apr 15;37(8):1060-2.A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects.
REF 64J Med Chem. 1995 Sep 15;38(19):3681-716.Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.
REF 65J Med Chem. 2010 Oct 14;53(19):7021-34.Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for |A(1)-adrenoceptors.
REF 66Bioorg Med Chem. 2007 Jun 1;15(11):3649-60. Epub 2007 Mar 21.Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-adrenoceptor antagonism.
REF 67J Med Chem. 1986 Oct;29(10):2000-3.Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists.
REF 68J Med Chem. 1995 May 26;38(11):1998-2008.Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
REF 69J Med Chem. 2007 Aug 9;50(16):3883-90.Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 2: A hybrid strategy combining key fragments of HTS hits.
REF 70J Med Chem. 1996 Jan 5;39(1):143-8.3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
REF 71J Med Chem. 1997 Apr 11;40(8):1252-7.N-[2-[(substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines: synthesis and wide range of antagonism at the human 5-HT1A receptor.
REF 72Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77.
REF 73Pharmacological properties of A-204176, a novel and selective alpha1A adrenergic agonist, in in vitro and in vivo models of urethral function. Life Sci. 2001 Nov 30;70(2):181-97.
REF 74CN patent application no. 104151292, Indole derivative or a pharmaceutically acceptable salt thereof.
REF 75Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
REF 76Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
REF 77In situ salt screening--a useful technique for discovery support and preformulation studies. Pharm Dev Technol. 1998 May;3(2):215-23.
REF 78The beta-adrenoceptor. Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 3):S146-53.
REF 79Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010051)
REF 80Drug Metabolism and Pharmacokinetics. Indian J Pharmacol. 2008 October; 40(Suppl 2): S91-S97.
REF 81Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66. Epub 2007 Aug 27.
REF 82In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists. Br J Pharmacol. 1999 May;127(1):252-8.
REF 83SDZ NVI 085, an alpha 1A-adrenoceptor agonist with 5-HT2A receptor antagonist properties. Eur J Pharmacol. 1996 Feb 15;297(1-2):83-6.
REF 84Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonists. Drug Metab Dispos. 2007 Aug;35(8):1435-45. Epub 2007 May 14.
REF 85Pharma & Vaccines. Product Development Pipeline. April 29 2009.
REF 86Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
REF 87Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.